196 related articles for article (PubMed ID: 18179992)
21. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM
J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116
[TBL] [Abstract][Full Text] [Related]
22. Sunitinib-induced thrombotic microangiopathy.
Noronha V; Punatar S; Joshi A; Desphande RV; Prabhash K
J Cancer Res Ther; 2016; 12(1):6-11. PubMed ID: 27072203
[TBL] [Abstract][Full Text] [Related]
23. [Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer].
van der Veldt AA; van den Eertwegh AJ; Boven E
Ned Tijdschr Geneeskd; 2007 May; 151(20):1142-7. PubMed ID: 17557672
[TBL] [Abstract][Full Text] [Related]
24. Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma.
Edeline J; Laguerre B; Rolland Y; Patard JJ
Ann Oncol; 2010 Jan; 21(1):186-7. PubMed ID: 19875754
[No Abstract] [Full Text] [Related]
25. Nephrotic Syndrome and Acute Renal Failure Apparently Induced by Sunitinib.
Chen YS; Chen CL; Wang JS
Case Rep Oncol; 2009 Oct; 2(3):172-176. PubMed ID: 20737033
[TBL] [Abstract][Full Text] [Related]
26. Sunitinib-induced hyperparathyroidism: a possible mechanism to altered bone homeostasis.
Baldazzi V; Tassi R; Lapini A; Lunghi A; Garofoli E; Caruso S; Carini M; Mazzanti R
Cancer; 2012 Jun; 118(12):3165-72. PubMed ID: 21956360
[TBL] [Abstract][Full Text] [Related]
27. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?
Rogiers A; Wolter P; Op de Beeck K; Thijs M; Decallonne B; Schöffski P
Thyroid; 2010 Mar; 20(3):317-22. PubMed ID: 20144039
[TBL] [Abstract][Full Text] [Related]
28. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
[TBL] [Abstract][Full Text] [Related]
29. Azithromycin-Induced, Biopsy-Proven Acute Interstitial Nephritis in an Adult Successfully Treated with Low-Dose Corticosteroids.
Woodruff AE; Meaney CJ; Hansen EA; Prescott GM
Pharmacotherapy; 2015 Nov; 35(11):e169-74. PubMed ID: 26598102
[TBL] [Abstract][Full Text] [Related]
30. Exfoliative esophagitis in a patient with metastatic renal cell carcinoma during sunitinib treatment.
Huang J; Wang T; Huang Y
Med Oncol; 2013 Mar; 30(1):436. PubMed ID: 23283650
[No Abstract] [Full Text] [Related]
31. Cardiac tamponade in a patient treated by sunitinib for metastatic renal cell carcinoma.
Yıldız I; Varol U; Şen F; Kılıç L
Anadolu Kardiyol Derg; 2014 Nov; 14(7):654-6. PubMed ID: 25163084
[No Abstract] [Full Text] [Related]
32. [Two cases of bowel perforation in patients with metastatic renal cancer treated with a molecularly targeted drug].
Kobayashi H; Ashikari A; Namitome R; Yagi Y; Kohno Y; Nishiyama T; Saito S
Nihon Hinyokika Gakkai Zasshi; 2012 Sep; 103(5):660-4. PubMed ID: 23342925
[TBL] [Abstract][Full Text] [Related]
33. [Partial nephrectomy after neoadjuvant administration of sunitinib facilitates preservation of a solitary kidney].
von Klot C; Becker JU; Grünwald V; Peters I; Kuczyk MA; Merseburger AS
Aktuelle Urol; 2012 Sep; 43(5):337-9. PubMed ID: 22911381
[TBL] [Abstract][Full Text] [Related]
34. Sunitinib-related high-grade proteinuria and allograft dysfunction in a kidney recipient: a rare case report.
Ko HC; Lee HP; Wu JD; Ma TL; Shen CH; Lin CT; Cheng MC; Jou YC
BMC Nephrol; 2022 Apr; 23(1):150. PubMed ID: 35436872
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Grandinetti CA; Goldspiel BR
Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib.
Bamias A; Lainakis G; Manios E; Koroboki E; Gyftaki R; Zakopoulos N; Dimopoulos MA
J Chemother; 2009 Jun; 21(3):347-50. PubMed ID: 19567357
[TBL] [Abstract][Full Text] [Related]
37. Metastatic renal cell carcinoma with partial response to sunitinib complicated by ureteral obstruction from necrotic tumor.
Meeks JJ; Kasper KA; Yang X; Kuzel TM; Smith ND
Urology; 2009 Feb; 73(2):444.e11-2. PubMed ID: 18384863
[TBL] [Abstract][Full Text] [Related]
38. Life-threatening complications associated with the tyrosine kinase inhibitor sunitinib malate.
Lim TJ; Lee JH; Chang SG; Lee CH; Min GE; Yoo KH; Jeon SH
Urol Int; 2010; 85(4):475-8. PubMed ID: 20975258
[TBL] [Abstract][Full Text] [Related]
39. Pleural and pericardial effusions combined with ascites in a patient with severe sunitinib-induced hypothyroidism.
Kust D; Kruljac I; Peternac AŠ; Ostojić J; Prpić M; Čaržavec D; Gaćina P
Acta Clin Belg; 2016 Jun; 71(3):175-7. PubMed ID: 26319226
[TBL] [Abstract][Full Text] [Related]
40. [Leg ulcerations and sunitinib].
Guyot-Caquelin P; Granel-Brocard F; Cuny JF; Trechot P; Spaeth D; Marchal A; Barbaud A; Schmutz JL
Ann Dermatol Venereol; 2010 Oct; 137(10):626-9. PubMed ID: 20932442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
